NCT06380270View on ClinicalTrials.gov

Evaluation of Safety and Human Tolerance of Oral Probiotic Streptococcus Salivarius eK12

NACompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

August 25, 2025

Study Completion Date

August 25, 2025

Conditions
SafetyTolerability
Interventions
DIETARY_SUPPLEMENT

Oral probiotic Streptococcus salivarius eK12

Bactoblis® EVOL (containing 10 billion CFU of S. salivarius eK12)

OTHER

Placebo

Orally dissolving placebo tablets

Trial Locations (1)

90250

Jam Ghulam Qadir Civil Hospital, Hub

All Listed Sponsors
collaborator

Università degli Studi dell'Insubria

OTHER

lead

Liaquat University of Medical & Health Sciences

OTHER

NCT06380270 - Evaluation of Safety and Human Tolerance of Oral Probiotic Streptococcus Salivarius eK12 | Biotech Hunter | Biotech Hunter